A Multicenter Prospective Open-label Single Arm Trial to Safely Discontinue Antiviral Treatment in Patients With HBeAg-Negative Chronic Hepatitis B and Low HBsAg Concentrations (ADAPT)
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Asan Medical Center
- Enrollment
- 140
- Locations
- 5
- Primary Endpoint
- virological relapse
Study Overview
Brief Summary
Multicenter, Prospective Open-label Single Arm Trial Chronic hepatitis B male and female adults on antiviral treatment for hepatitis B, without cirrhosis who are currently HBV DNA (-) and HBeAg (-) To evaluate the safety and efficacy of stopping long-term antiviral therapy in chronic hepatitis B patients without cirrhosis who are currently HBV DNA (-) and HBeAg (-)
Detailed Description
This clinical trial is a multicenter, Prospective Open-label Single Arm Trial to evaluate the safety and efficacy of stopping long-term antiviral therapy in chronic hepatitis B patients without cirrhosis who are currently HBV DNA (-) and HBeAg (-).
Approximately 140 subjects meeting eligibility criteria will be enrolled a Intervention Arm as below;
- Intervention Arm: 140 subjects, discontinue antiviral treatment (stop group)
Participants are scheduled to be followed up to 48 weeks. Patients are retreated with nucleos(t)ide analogues that had been prescribed previously if they fulfill one of the following criteria: 1) HBV DNA >2,000 IU/mL, 2) at the participant's request or at the treating investigator's discretion, 3) progression to liver cirrhosis, or 4) development of hepatocellular carcinoma.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Supportive Care
- Masking
- None
Eligibility Criteria
- Ages
- 19 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Willing and able to provide written informed consent prior to study entry
- •Age ≥19 years and ≤65 years at the time of screening
- •HBsAg titer <3,000 IU/mL at the time of screening
- •Antiviral treatment continued at least 2 years and HBeAg (-) at the time of screening
- •Undetectable HBV DNA level at the time of screening
- •Serum ALT level <80 IU/mL at the time of screening
- •Estimated creatinine clearance ≥30 ml/min (by calculation of creatinine clearance or using the CKD-EPI equation)
- •Ability to comply with all study requirements
Exclusion Criteria
- •Confirmed known co-infection with HCV, HIV, or HDV
- •Evidence of liver cirrhosis defined as meeting any of the following criteria:
- •Current alcohol (60g/day) or substance abuse judged by the investigator that will potentially interfere with subject compliance (1) Splenomegaly (>12 cm) assessed by ultrasound, CT, or MRI (2) Fibroscan ≥9.0 kPa (3) Platelet count <150,000/mm3 However, if the above criteria were satisfied at the time of antiviral treatment initiation, subjects may be eligible if they have low possibility of having liver cirrhosis with improvement in liver function by long-term antiviral treatment, following the opinion of the investigator.
- •Any history of clinical hepatic decompensation (e.g., ascites, encephalopathy, variceal hemorrhage) within 12 months prior to the screening or Child-Pugh score of ≥7 at the time of screening
- •Currently on or have received therapy with Interferon or immunosuppressant (including systemic chemotherapy) within 12 months prior to the screening
- •Requirement for chronic use of systemic immunosuppressant including, but not limited to, corticosteroid (prednisone equivalent of >40 mg/day for >2 weeks), azathioprine, or monoclonal antibodies
- •Received solid organ or bone marrow transplant
- •Any other clinical conditions (cardiovascular, respiratory, neurologic, or renal conditions) or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements.
- •History or current evidence of hepatocellular carcinoma (HCC), or high α-fetoprotein (AFP) > 20 ng/mL. (But, the patients with AFP > 20 ng/mL can be enrolled and there is no evidence of HCC by dynamic CT or MRI perfomred within 4 months prior to the screening)
- •Malignancy other than hepatocellular carcinoma within the 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (within 2 years prior to screening with confirmation of no evidence of disease). Subjects under evaluation for possible malignancy are not eligible.
- •Concurrent enrollment in another clinical study for other type of antiviral treatment for CHB or immune modulatory drug within 3 months prior to Screening, participation to an observational (non-interventional) clinical studies or interventional studies not using anti-HBV or immune modulatory drugs, or during the follow-up period of an interventional study are not exclusion criteria.
- •Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study
Arms & Interventions
Treatment Arm A
discontinue antiviral treatment
Intervention: Stop group (Drug)
Outcomes
Primary Outcomes
virological relapse
Time Frame: Change from baseline in HBV DNA result at 6month and 12month
Proportion of virological relapse defined as HBV DNA ≥2,000 IU/mL
virological relapse
Time Frame: Change from baseline in HBV DNA result in 48 weeks
Proportion of virological relapse defined as HBV DNA ≥2,000 IU/mL
Secondary Outcomes
- Proportion of clinical relapse(at 6month and 12 month)
- hospital admission(From baseline, clinical events will be collected within 12month)
- Biochemical relapse(From baseline, clinical events will be collected within 48 weeks)
- Retreatment(48 weeks)
- HBsAg seroclearance(48 weeks)
- Hepatic decompensation(48 weeks)
- ALT flare(48 weeks)
Investigators
Young-Suk Lim
PhD
Asan Medical Center